BR112020010479A2 - sistemas cas9 geneticamente modificados para modificação de genoma eucariótico - Google Patents
sistemas cas9 geneticamente modificados para modificação de genoma eucariótico Download PDFInfo
- Publication number
- BR112020010479A2 BR112020010479A2 BR112020010479-5A BR112020010479A BR112020010479A2 BR 112020010479 A2 BR112020010479 A2 BR 112020010479A2 BR 112020010479 A BR112020010479 A BR 112020010479A BR 112020010479 A2 BR112020010479 A2 BR 112020010479A2
- Authority
- BR
- Brazil
- Prior art keywords
- genetically modified
- sequence
- protein
- fact
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
- C12N9/226—Class 2 CAS enzyme complex, e.g. single CAS protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/85—Fusion polypeptide containing an RNA binding domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862631304P | 2018-02-15 | 2018-02-15 | |
| US62/631,304 | 2018-02-15 | ||
| US201862720525P | 2018-08-21 | 2018-08-21 | |
| US62/720,525 | 2018-08-21 | ||
| PCT/US2019/018335 WO2019161290A1 (en) | 2018-02-15 | 2019-02-15 | Engineered cas9 systems for eukaryotic genome modification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020010479A2 true BR112020010479A2 (pt) | 2020-11-24 |
Family
ID=65995829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020010479-5A BR112020010479A2 (pt) | 2018-02-15 | 2019-02-15 | sistemas cas9 geneticamente modificados para modificação de genoma eucariótico |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10767193B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3752607A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7109547B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR102465067B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111902536B (cg-RX-API-DMAC7.html) |
| AU (3) | AU2019222568B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020010479A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3281020A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL321024A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202007382TA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019161290A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| US11111492B2 (en) * | 2017-03-06 | 2021-09-07 | Florida State University Research Foundation, Inc. | Genome engineering methods using a cytosine-specific Cas9 |
| CN112654710A (zh) | 2018-05-16 | 2021-04-13 | 辛瑟高公司 | 用于指导rna设计和使用的方法和系统 |
| AU2019291918B2 (en) | 2018-06-29 | 2025-06-12 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| US10913941B2 (en) | 2019-02-14 | 2021-02-09 | Metagenomi Ip Technologies, Llc | Enzymes with RuvC domains |
| SG11202108812SA (en) | 2019-02-15 | 2021-09-29 | Sigma Aldrich Co Llc | Crispr/cas fusion proteins and systems |
| EP4219700A1 (en) | 2019-03-07 | 2023-08-02 | The Regents of the University of California | Crispr-cas effector polypeptides and methods of use thereof |
| JP7785002B2 (ja) | 2019-11-05 | 2025-12-12 | ペアーワイズ プランツ サービシズ, インコーポレイテッド | 対立遺伝子のrnaにコードされたdnaの置換のための組成物および方法 |
| KR20220116512A (ko) | 2019-12-17 | 2022-08-23 | 시그마-알드리치 컴퍼니., 엘엘씨 | 박테로이데스의 게놈편집 |
| GB2617659B (en) * | 2020-02-14 | 2024-05-01 | Metagenomi Inc | Enzymes with RuvC domains |
| CA3177051A1 (en) * | 2020-03-31 | 2021-10-07 | Metagenomi, Inc. | Class ii, type ii crispr systems |
| CN112159801B (zh) * | 2020-07-13 | 2022-11-15 | 复旦大学 | SlugCas9-HF蛋白、含有SlugCas9-HF蛋白的基因编辑系统及应用 |
| KR102679001B1 (ko) * | 2020-09-21 | 2024-06-28 | 고려대학교 산학협력단 | 신규의 개량된 염기 편집 또는 교정용 융합단백질 및 이의 용도 |
| AU2021374974A1 (en) * | 2020-11-06 | 2023-05-25 | Pairwise Plants Services, Inc. | Compositions and methods for rna-encoded dna-replacement of alleles |
| CN119452085A (zh) | 2021-08-27 | 2025-02-14 | 宏基因组学公司 | 具有ruvc结构域的酶 |
| CN113717960B (zh) * | 2021-08-27 | 2023-07-18 | 电子科技大学 | 一种新Cas9蛋白、CRISPR-Cas9基因组定向编辑载体及基因组编辑方法 |
| KR20240110603A (ko) | 2021-11-24 | 2024-07-15 | 메타지노미, 인크. | 엔도뉴클레아제 시스템 |
| CN114657181B (zh) * | 2022-04-01 | 2023-08-25 | 安徽大学 | 一种靶向H1.4的sgRNA以及H1.4基因编辑方法 |
| EP4592322A4 (en) * | 2022-09-23 | 2026-08-05 | Chuang Woei Jer | Fusion protein targeting alpha(IIB)beta3 integrin and containing a tissue plasminogen activator or a variant thereof, and its use |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030232430A1 (en) | 2001-11-26 | 2003-12-18 | Advanced Cell Technology | Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| DK3363902T3 (da) | 2012-12-06 | 2020-01-02 | Sigma Aldrich Co Llc | Crispr-baseret genommodifikation og -regulering |
| KR102955556B1 (ko) * | 2012-12-12 | 2026-04-22 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물 |
| WO2014197748A2 (en) | 2013-06-05 | 2014-12-11 | Duke University | Rna-guided gene editing and gene regulation |
| US9074199B1 (en) * | 2013-11-19 | 2015-07-07 | President And Fellows Of Harvard College | Mutant Cas9 proteins |
| EP3097212A4 (en) * | 2014-01-24 | 2017-10-04 | North Carolina State University | Methods and compositions for sequences guiding cas9 targeting |
| EP3981876A1 (en) * | 2014-03-26 | 2022-04-13 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating sickle cell disease |
| US10450584B2 (en) * | 2014-08-28 | 2019-10-22 | North Carolina State University | Cas9 proteins and guiding features for DNA targeting and genome editing |
| EP3845655B1 (en) * | 2014-10-01 | 2025-01-01 | The General Hospital Corporation | Methods for increasing efficiency of nuclease-induced homology-directed repair |
| DK3604527T3 (da) | 2016-06-02 | 2021-05-31 | Sigma Aldrich Co Llc | Anvendelse af programmerbare dna-bindingsproteiner til at forbedre målrettet genommodifikation |
| CN109688820B (zh) | 2016-06-24 | 2023-01-10 | 科罗拉多州立大学董事会(法人团体) | 用于生成条形码化组合文库的方法 |
| EP4650364A3 (en) | 2016-07-06 | 2026-01-21 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of pain related disorders |
| US11242513B2 (en) * | 2016-12-14 | 2022-02-08 | Wageningen Universiteit | Thermostable Cas9 nucleases |
| KR102655021B1 (ko) * | 2017-07-11 | 2024-04-04 | 시그마-알드리치 컴퍼니., 엘엘씨 | 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용 |
| CA3071769A1 (en) | 2017-07-31 | 2019-02-07 | Reflection Biotechnologies Limited | Cellular models of and therapies for ocular diseases |
-
2019
- 2019-02-15 WO PCT/US2019/018335 patent/WO2019161290A1/en not_active Ceased
- 2019-02-15 US US16/277,823 patent/US10767193B2/en active Active
- 2019-02-15 CA CA3281020A patent/CA3281020A1/en active Pending
- 2019-02-15 IL IL321024A patent/IL321024A/en unknown
- 2019-02-15 IL IL274528A patent/IL274528B2/en unknown
- 2019-02-15 KR KR1020207026571A patent/KR102465067B1/ko active Active
- 2019-02-15 KR KR1020227002190A patent/KR102494449B1/ko active Active
- 2019-02-15 AU AU2019222568A patent/AU2019222568B2/en active Active
- 2019-02-15 EP EP19714890.1A patent/EP3752607A1/en active Pending
- 2019-02-15 CA CA3084020A patent/CA3084020C/en active Active
- 2019-02-15 BR BR112020010479-5A patent/BR112020010479A2/pt unknown
- 2019-02-15 KR KR1020237003098A patent/KR102684890B1/ko active Active
- 2019-02-15 SG SG11202007382TA patent/SG11202007382TA/en unknown
- 2019-02-15 JP JP2020531575A patent/JP7109547B2/ja active Active
- 2019-02-15 CN CN201980013625.2A patent/CN111902536B/zh active Active
-
2020
- 2020-07-30 US US16/943,813 patent/US12297449B2/en active Active
-
2022
- 2022-01-11 AU AU2022200130A patent/AU2022200130B2/en active Active
- 2022-05-23 JP JP2022083820A patent/JP7559005B2/ja active Active
-
2024
- 2024-04-04 AU AU2024202158A patent/AU2024202158B2/en active Active
- 2024-07-18 JP JP2024114477A patent/JP2024161376A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7559005B2 (ja) | 真核ゲノム修飾のための操作されたCas9システム | |
| KR102458395B1 (ko) | 프로그램가능한 dna 결합 단백질을 사용한, 표적화된 게놈 변형의 개선 | |
| JP2020530992A (ja) | Crispr/casアクチベーターシステムのための合成ガイドrna | |
| US20230287377A1 (en) | Crispr/cas fusion proteins and systems | |
| JP7629673B2 (ja) | ゲノム改変のための高忠実度SpCas9ヌクレアーゼ | |
| BR122025004697A2 (pt) | Sistema para modificar uma sequência cromossômica em uma célula eucariótica, pluralidade de ácidos nucleicos, vetor, célula eucariótica, proteína de fusão, composição e usos | |
| BR122025004697B1 (pt) | Sistemas para modificar um genoma eucariótico, pluralidade de ácidos nucleicos, vetor, e proteína de fusão | |
| HK40040051A (en) | Engineered cas9 systems for eukaryotic genome modification | |
| HK40040051B (en) | Engineered cas9 systems for eukaryotic genome modification | |
| BR112019028261A2 (pt) | uso de domínios de proteína de interação com nucleossomo para melhorar modificação de genoma direcionada | |
| BR122025010024A2 (pt) | Proteína de fusão de interação com nucleossomo, composição, ácido nucleico, complexo e células eucarióticas in vitro | |
| BR112019028261B1 (pt) | Proteína de fusão de interação com nucleossomo, complexo e método para aumentar a eficiência do genoma alvo ou da modificação epigenética em uma célula eucariótica | |
| BR122024024008A2 (pt) | Método para aumentar a eficiência do genoma alvo ou da modificação epigenética em uma célula eucariótica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122025004697-3 PROTOCOLO 870250019360 EM 12/03/2025 14:43. |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |